JP2024513492A - がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法 - Google Patents

がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法 Download PDF

Info

Publication number
JP2024513492A
JP2024513492A JP2023561858A JP2023561858A JP2024513492A JP 2024513492 A JP2024513492 A JP 2024513492A JP 2023561858 A JP2023561858 A JP 2023561858A JP 2023561858 A JP2023561858 A JP 2023561858A JP 2024513492 A JP2024513492 A JP 2024513492A
Authority
JP
Japan
Prior art keywords
alkyl
inhibitor
hydrogen
cancer
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513492A5 (https=
Inventor
エングストーム、ラルス、ダニエル
オルソン、ペーター
クリステンセン、ジェームズ、ガイル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of JP2024513492A publication Critical patent/JP2024513492A/ja
Publication of JP2024513492A5 publication Critical patent/JP2024513492A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023561858A 2021-04-08 2022-04-05 がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法 Pending JP2024513492A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163172639P 2021-04-08 2021-04-08
US63/172,639 2021-04-08
US202163252998P 2021-10-06 2021-10-06
US63/252,998 2021-10-06
PCT/US2022/023394 WO2022216648A1 (en) 2021-04-08 2022-04-05 Combination therapies using prmt5 inhibitors for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024513492A true JP2024513492A (ja) 2024-03-25
JP2024513492A5 JP2024513492A5 (https=) 2025-04-14

Family

ID=81748231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561858A Pending JP2024513492A (ja) 2021-04-08 2022-04-05 がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法

Country Status (9)

Country Link
US (2) US12128048B2 (https=)
EP (1) EP4319754A1 (https=)
JP (1) JP2024513492A (https=)
KR (1) KR20230167053A (https=)
AU (1) AU2022253455A1 (https=)
CA (1) CA3214530A1 (https=)
IL (1) IL307392A (https=)
MX (1) MX2023011856A (https=)
WO (1) WO2022216648A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022500385A (ja) * 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
EA202190749A1 (ru) * 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
US20240208912A1 (en) * 2021-03-11 2024-06-27 Mirati Therapeutics, Inc. MTA-Cooperative PRMT5 Inhibitors
WO2023098439A1 (zh) * 2021-11-30 2023-06-08 上海和誉生物医药科技有限公司 一种吡唑衍生物，其制备方法和在药学上的应用
WO2023125540A1 (zh) * 2021-12-27 2023-07-06 南京明德新药研发有限公司 吡唑-1(2h)-酞嗪酮类化合物及其应用
WO2023202626A1 (zh) * 2022-04-22 2023-10-26 北京望实智慧科技有限公司 稠和哒嗪酮化合物作为prmt5抑制剂
CN119301101A (zh) * 2022-07-29 2025-01-10 四川科伦博泰生物医药股份有限公司 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途
WO2024027703A1 (zh) * 2022-08-02 2024-02-08 上海艾力斯医药科技股份有限公司 一种prmt5抑制剂、其制备方法及应用
CN120265615A (zh) * 2022-11-29 2025-07-04 正大天晴药业集团股份有限公司 含有二氢酞嗪的化合物
JP2026506429A (ja) * 2022-12-21 2026-02-25 アムジエン・インコーポレーテツド Ｍｔａ協同的ｐｒｍｔ５阻害薬を使用した癌治療
CN120712260A (zh) * 2023-02-21 2025-09-26 正大天晴药业集团股份有限公司 含有二氢酞嗪和烯基的化合物及其用途
WO2025157289A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和krasg12c抑制剂的药物组合物
WO2025217015A1 (en) * 2024-04-08 2025-10-16 Mirati Therapeutics, Inc. Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102444509B1 (ko) 2016-05-18 2022-09-19 미라티 테라퓨틱스, 인크. Kras g12c 억제제
LT3710439T (lt) 2017-11-15 2023-05-10 Mirati Therapeutics, Inc. Kras g12c inhibitoriai
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
JP2021176819A (ja) * 2018-07-31 2021-11-11 アステラス製薬株式会社 キナゾリン化合物を有効成分とする医薬組成物
ES2961253T3 (es) 2018-08-31 2024-03-11 Mirati Therapeutics Inc Inhibidores de KRas G12C
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
IL290341B2 (en) 2019-09-12 2024-11-01 Mirati Therapeutics Inc Mta-cooperative prmt5 inhibitors
KR20220086628A (ko) 2019-10-22 2022-06-23 루핀 리미티드 Prmt5 저해제의 약학적 조합물

Also Published As

Publication number Publication date
US20240423987A1 (en) 2024-12-26
US20220331324A1 (en) 2022-10-20
KR20230167053A (ko) 2023-12-07
IL307392A (en) 2023-12-01
MX2023011856A (es) 2024-01-08
WO2022216648A1 (en) 2022-10-13
US12128048B2 (en) 2024-10-29
AU2022253455A1 (en) 2023-11-02
CA3214530A1 (en) 2022-10-13
EP4319754A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
JP2024513492A (ja) がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法
JP2024513494A (ja) がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法
US8124649B2 (en) Oxindole compounds
PT1591446E (pt) Compostos de tienopirimidina e sua utilização
KR20240095421A (ko) 암 치료를 위해 prmt5 억제제를 사용하는 병용 요법
AU2023334579A1 (en) Combination therapies using prmt5 inhibitors and bcl-2 family inhibitors for the treatment of cancer
CN117769421A (zh) 使用prmt5抑制剂治疗癌症的组合疗法
WO2025217015A1 (en) Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer
CN117769420A (zh) 使用prmt5抑制剂治疗癌症的组合疗法
EA051338B1 (ru) Комбинированная терапия с использованием ингибиторов prmt5 для лечения рака
WO2025217007A1 (en) Combination therapies using prmt5 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025217008A1 (en) Combination therapies using prmt5 inhibitors and sos1 inhibitors for the treatment of cancer
TWI867817B (zh) 一種二噁烷並喹啉類化合物的鹽、其晶型以及它們的製備方法及用途
BR112018012756B1 (pt) Compostos heterocíclicos como imunomoduladores, seu uso e composição farmacêutica que os compreende

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231207

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250205

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250404